UK Markets close in 6 hrs 15 mins

BNP Paribas Primary New Issues: BIOFARMA GROUP - NO STAB Notice

·1-min read
BNP Paribas Primary New Issues
BNP Paribas Primary New Issues

9TH May 2022

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

BIOFARMA Group

Post-stabilisation Period Announcement

NO STABILISATION CARRIED OUT

[Further to the pre-stabilisation period announcement dated 5th May 2022 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Securities

Issuer:

BIOFARMA GROUP / KEPLER S.P.A.

Guarantor(s) (if any):

[insert name(s)]

Aggregate nominal amount:

EUR 345,000,000,0000

Description:

FRN due 15 May 2029

Offer price:

96.00

Stabilisation Manager(s)

Name(s):

Left lead: BNP Paribas
Joint glo co: BNPP/Mediobanca/Nomura
Bookrunner: Banca IMI

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting